Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
The GeneSight (GS) Psychotropic Test (AssureRx Health, Inc.) measures individual variations in drug-related genes and recommends optimal drug choices for individual patients. A clinical study will be conducted to validate novel gene markers of antipsychotic-induced weight gain for use in an enhanced version of GS. Sarah Groleau will be responsible for genotyping DNA from 600 schizophrenia patients to evaluate which of the significant gene variants (UofT/CAMH) predict the most troubling side effect of antipsychotic medications: weight gain and metabolic syndrome. She will also be involved in economic analyses of financial burden in failed treatments, with MaRS EXCITE, to position the GS tests for OHIP reimbursement. In addition, Sarah will shadow ARxC personnel, gaining exposure to all aspects of the companys function. Sarahs project will provide AssureRx Canada with substantial intellectual capital and access to research expertise at CAMH, enabling accelerated timelines for AssureRx product release and Ministry of Health licensing.
Jim Kennedy
Sarah Groleau
AssureRx Canada
Psychology
Life sciences
University of Toronto
Elevate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.